DarioHealth Return on Equity (ROE) Growth & History (DRIO)
DarioHealth's return on equity was −59.62% for fiscal 2025.
View full DarioHealth company overviewDarioHealth annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −59.62% | +6.07 pp |
| 2024 | 2024-12-31 | −65.68% | +20.35 pp |
| 2023 | 2023-12-31 | −86.04% | −10.90 pp |
| 2022 | 2022-12-31 | −75.14% | +59.89 pp |
| 2021 | 2021-12-31 | −135.02% | −9.85 pp |
| 2020 | 2020-12-31 | −125.18% | +2.33 pp |
| 2019 | 2019-12-31 | −127.51% | +149.23 pp |
| 2018 | 2018-12-31 | −276.74% | — |
DarioHealth quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −13.49% | +5.38 pp |
| Q1 2026 | 2026-03-31 | −12.66% | +0.00 pp |
| Q4 2025 | 2025-12-31 | −12.64% | +2.11 pp |
| Q3 2025 | 2025-09-30 | −15.07% | +4.42 pp |
| Q2 2025 | 2025-06-30 | −18.87% | −0.24 pp |
| Q1 2025 | 2025-03-31 | −12.66% | −2.13 pp |
| Q4 2024 | 2024-12-31 | −14.76% | +7.88 pp |
| Q3 2024 | 2024-09-30 | −19.48% | +2.00 pp |
| Q2 2024 | 2024-06-30 | −18.63% | +3.42 pp |
| Q1 2024 | 2024-03-31 | −10.54% | +6.33 pp |
| Q4 2023 | 2023-12-31 | −22.64% | −7.71 pp |
| Q3 2023 | 2023-09-30 | −21.49% | −4.91 pp |
| Q2 2023 | 2023-06-30 | −22.05% | −5.19 pp |
| Q1 2023 | 2023-03-31 | −16.87% | −0.93 pp |
| Q4 2022 | 2022-12-31 | −14.94% | +7.79 pp |
| Q3 2022 | 2022-09-30 | −16.58% | +3.59 pp |
| Q2 2022 | 2022-06-30 | −16.86% | −1.44 pp |
| Q1 2022 | 2022-03-31 | −15.94% | +5.38 pp |
| Q4 2021 | 2021-12-31 | −22.72% | +5.75 pp |
| Q3 2021 | 2021-09-30 | −20.17% | +7.55 pp |
| Q2 2021 | 2021-06-30 | −15.42% | +13.55 pp |
| Q1 2021 | 2021-03-31 | −21.32% | +36.33 pp |
| Q4 2020 | 2020-12-31 | −28.48% | +8.13 pp |
| Q3 2020 | 2020-09-30 | −27.72% | +28.38 pp |
| Q2 2020 | 2020-06-30 | −28.97% | +79.11 pp |
| Q1 2020 | 2020-03-31 | −57.65% | +26.42 pp |
| Q4 2019 | 2019-12-31 | −36.60% | +14.94 pp |
| Q3 2019 | 2019-09-30 | −56.09% | −0.31 pp |
| Q2 2019 | 2019-06-30 | −108.08% | −6.78 pp |
| Q1 2019 | 2019-03-31 | −84.07% | −32.46 pp |
| Q4 2018 | 2018-12-31 | −51.54% | +13.40 pp |
| Q3 2018 | 2018-09-30 | −55.79% | +3.27 pp |
| Q2 2018 | 2018-06-30 | −101.30% | +12.59 pp |
| Q1 2018 | 2018-03-31 | −51.61% | — |
| Q4 2017 | 2017-12-31 | −64.94% | — |
| Q3 2017 | 2017-09-30 | −59.06% | −46.28 pp |
| Q2 2017 | 2017-06-30 | −113.89% | −50.58 pp |
| Q3 2016 | 2016-09-30 | −12.78% | — |
| Q2 2016 | 2016-06-30 | −63.31% | — |
| Q1 2016 | 2016-03-31 | −78.53% | — |
| Q3 2013 | 2013-09-30 | −692.14% | — |
DarioHealth return on equity trends
Over the last five fiscal years, DarioHealth's return on equity increased from −125.18% to −59.62%, a change of +65.56 percentage points. The latest reported quarter, Q2 2026, shows −13.49%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review DarioHealth source filings ↗